Skip to content
DataLookout
Menu

PearlstoneNCT07827599

A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Minor Trial sites expanded: 8 → 20 locations
  2. Notable Recruitment opened
    • Trial sites expanded: 0 → 8 locations
    • Start date changed from estimate of Sep 22, 2026 to Oct 16, 2026
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants who are Infected With Influenza Virus (Reverse Transcription - Polymerase Chain Reaction [RT-PCR] Positive), and Present With Fever and at Least one Respiratory Symptom
Timeframe: From Day 1 up to Day 10

Secondary (3)

Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive), and Present With Fever or at Least one Influenza Symptom (Respiratory or Systemic)
Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive) Regardless of Body Temperature or Influenza Symptoms
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Arms and interventions

Baloxavir MarboxilExperimental

HHCs will receive baloxavir marboxil according to their body weight as outlined in the protocol.

PlaceboPlacebo comparator

HHCs will receive baloxavir marboxil matching placebo according to their body weight as outlined in the protocol.

No InterventionNo intervention

Index participants will not receive any study treatment but will continue to receive SOC treatment for influenza, as per the local guidelines.

Drugs: Baloxavir marboxil, Placebo

Sites

20 sites in 1 country